Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data

Liver International

Volumn 31, Issue SUPPL. 2, 2011, Pages 4-17

  Kershenobich, David ^a   Razavi, Homie A ^b   Cooper, Curtis L ^c   Alberti, Alfredo ^d   Dusheiko, Geoffrey M ^e   Pol, Stanislas ^f   Zuckerman, Eli ^g   Koike, Kazuhiko ^h   Han, Kwang Hyub ⁱ   Wallace, Carolyn M ^b   Zeuzem, Stefan ^j   Negro, Francesco ^k  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b Center for Disease Analysis   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF PADOVA   (Italy)

^e ROYAL FREE HOSPITAL   (United Kingdom)

^f INSERM   (France)

^g CARMEL MEDICAL CENTER   (Israel)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ Yonsei University College of Medicine   (South Korea)

^j UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^k GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

Diagnosis; Disease burden; Epidemiology; HCV infection; Hepatitis C; Incidence; Mortality; Prevalence; Sensitivity analysis; System modelling; Treatment rate

Indexed keywords

ARTICLE; COMPUTER SIMULATION; DISEASE SURVEILLANCE; FORECASTING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; POPULATION SIZE; PREVALENCE; SENSITIVITY ANALYSIS; UNITED STATES; VALIDATION STUDY;

ADULT; AGED; BAYES THEOREM; COMPUTER SIMULATION; EPIDEMICS; EUROPE; FEMALE; FORECASTING; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, STATISTICAL; NUMERICAL ANALYSIS, COMPUTER-ASSISTED; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNCERTAINTY; UNITED STATES;

EID: 79958733325     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02535.x     Document Type: Article

References (76)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
2. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-100.
3. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36: S1-20.
4. Pereira A. Health and economic consequences of HCV lookback. Transfusion 2001; 41: 832-9.
5. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50: 1750-5.
6. Deuffic-Burban S, Mathurin P, Valleron AJ. Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. Stat Methods Med Res 2009; 18: 233-52.
7. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107-15.
8. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-37.
9. Sweeting MJ, De Angelis D, Hickman M, Ades AE. Estimating hepatitis C prevalence in England and Wales by synthesizing evidence from multiple data sources. Assessing data conflict and model fit. Biostatistics 2008; 9: 715-34.
10. Sweeting MJ, De Angelis D, Neal KR, et al. Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment. J Clin Epidemiol 2006; 59: 144-52.
11. Terrault NA, Im K, Boylan R, et al. Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C. Clin Gastroenterol Hepatol 2008; 6: 1403-11.
12. Tramarin A, Gennaro N, Compostella FA, et al. HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. Curr Pharm Des 2008; 14: 1655-60.
13. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998; 280: 2088-93.
14. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005; 42: 711-23.
15. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-9.
16. Buti M, San Miguel R, Brosa M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42: 639-45.
17. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
18. Howard R, Matheson JE. Influence diagram retrospective. Decis Anal 2005; 2: 144-7.
19. Keeney RL, Raiffa H. Decisions with Multiple Objectives: Preferences and Value Tradeoffs. Cambridge: Cambridge University Press, 1993.
20. Keeney RL. Value Focused Thinking: A Path to Creative Decisionmaking. President and Fellow of Harvard College, 1992. Harvard University Press, Cambridge, MA, USA.
21. Hammond JS, Keeney RL, Raiffa H. Smart Choices: A Practical Guide to Making Better Life Decisions. Harvard Business School Press, Boston, MA, USA 1999.
22. Kirkwood GW. Strategic Decision Making: Multiobjective Decision Analysis with Spreadsheets. Belmont, CA: Duxbury Press, 1997.
23. Grelk BJ, Kloeber JM, Jackson JA, Parnell GS, Deckro RF. Making the CERCLA criteria analysis of remedial alternatives more objective. Remediation 1998; 8: 87-105.
24. Hamill JT, Deckro RF, Kloeber JM. Evaluating information assurance strategies. Decis Support Sys 2005; 39: 463-84.
25. Edwards W, Barron FH. SMARTS and SMARTER: improved simple methods for multiattribute utility measurements. Organ Behav Hum Decis Process 1994; 60: 306-25.
26. Centers for Disease Control and Prevention. Guidelines for Viral Hepatitis Surveillance and Case Management. Atlanta, GA: US Department of Health, Education, and Welfare, Public Health Service, Atlanta, GA, USA 2005.
27. Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis - United States, 2007. MMWR Surveill Summ 2009; 58: 1-27.
28. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-98.
29. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-82.
30. Wiegand J, Deterding K, Cornberg M, Wedemeyer H. Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother 2008; 62: 860-5.
31. Corey KE, Ross AS, Wurcel A, et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol 2006; 4: 1278-82.
32. Kamal SM, Moustafa KN, Chen J, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006; 43: 923-31.
33. Morin T, Pariente A, Lahmek P, et al. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol 2010; 22: 157-66.
34. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908-14.
35. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B hepatitis study team. N Engl J Med 1992; 327: 1899-905.
36. Centers for Disease Control and Prevention. Hepatitis Surveillance. Hepatitis Surveillance/Center for Disease Control, Atlanta, GA, USA 2006.
37. Centers for Disease Control. Disease Burden from Viral Hepatitis A, B, and C in the United States. CDC Division of Viral Hepatitis - Statistics and Surveillance. Centers for Disease Control, 2007. Available at
38. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects. 2002 Population Database. United Nations, Department of Economic and Social Affairs, Population Division, 2005. Available at
39. Duberg AS, Torner A, Davidsdottir L, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat 2008; 15: 538-50.
40. McDonald SA, Hutchinson SJ, Bird SM, et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res 2009; 18: 271-83.
41. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368: 938-45.
42. United Nations, Statistical Office. Demographic yearbook/Annuaire dâemographique. Demographic Yearbook, 59th edn. United Nations, Statistical Office, New York, NY, USA 2007. Available at (accessed 9 October 2009).
43. United Nations and Statistical Office. Demographic Yearbook/Annuaire dâemographique 2006, 58th edn. Department of Economic and Social Affairs, Statistical Office, United Nations, 2008.
44. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 105-11.
45. Guiltinan AM, Kaidarova Z, Custer B, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167: 743-50.
46. Frischer M, Goldberg D, Rahman M, Berney L. Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994. Addiction 1997; 92: 419-27.
47. Kamper-Jorgensen M, Ahlgren M, Rostgaard K, et al. Survival after blood transfusion. Transfusion 2008; 48: 2577-84.
48. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
49. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
50. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in the United States: an estimate of true prevalence. Liver Int 2011. DOI: DOI: 10.1111/j.1478-3231.2011.02494.x. (in press).
51. Abdel-Hamid M, El-Daly M, El-Kafrawy S, et al. Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol 2002; 40: 1656-9.
52. Silva L, Parana R, Mota E, et al. Prevalence of hepatitis C virus in urban and rural populations of northeast Brazil-pilot study. Arq Gastroenterol 1995; 32: 168-71.
53. Glynn SA, Kleinman SH, Schreiber GB, et al. Trends in incidence and prevalence of major transfusion-transmissible viral infections in US blood donors, 1991 to 1996. Retrovirus Epidemiology Donor Study (REDS). JAMA 2000; 284: 229-35.
54. Santos-Lopez G, Sosa-Jurado F, Vallejo-Ruiz V, Melendez-Mena D, Reyes-Leyva J. Prevalence of hepatitis C virus in the Mexican population: a systematic review. J Infect 2008; 56: 281-90.
55. Bornschlegel K, Berger M, Garg RK, et al. Prevalence of hepatitis C infection in New York City, 2004. J Urban Health 2009; 86: 909-17.
56. Brady KA, Weiner M, Turner BJ. Undiagnosed hepatitis C on the general medicine and trauma services of two urban hospitals. J Infect 2009; 59: 62-9.
57. Kilbourne AM, McCarthy JF, Himelhoch S, et al. Guideline-concordant hepatitis C virus testing and notification among patients with and without mental disorders. Gen Hosp Psychiatry 2008; 30: 495-500.
58. Klevens RM, Miller J, Vonderwahl C, et al. Population-based surveillance for hepatitis C virus, United States, 2006-2007. Emerg Infect Dis 2009; 15: 1499-502.
59. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.
60. Deuffic-Burban S, Wong JB, Valleron AJ, et al. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40: 319-26.
61. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 2005; 42: 1406-13.
62. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001; 34: 730-9.
63. Massard J, Ratziu V, Thabut D, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44: S19-24.
64. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-6.
65. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009; 50: 387-92.
66. Neal KR, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56: 1098-104.
67. Prasad L, Spicher VM, Negro F, Rickenbach M, Zwahlen M. Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss hepatitis C cohort study. J Viral Hepat 2009; 16: 644-9.
68. Harris HE, Ramsay ME, Andrews NJ. Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure. Epidemiol Infect 2006; 134: 472-7.
69. Harris HE, Ramsay ME, Andrews N, Eldridge KP. Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002; 324: 450-3.
70. Omland LH, Krarup H, Jepsen P, et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010; 53: 36-42.
71. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-8.e1.
72. Gish RG, Afdhal NH, Dieterich DT, Reddy KR. Management of hepatitis C virus in special populations: patient and treatment considerations. Clin Gastroenterol Hepatol 2005; 3: 311-8.
73. McDonald SA, Hutchinson SJ, Bird SM, et al. Excess morbidity in the hepatitis C-diagnosed population in Scotland, 1991-2006. Epidemiol Infect 2011; 139: 344-53.
74. Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-504.
75. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-81.
76. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.